PMID- 20739728
OWN - NLM
STAT- MEDLINE
DCOM- 20110307
LR  - 20221207
IS  - 1872-9061 (Electronic)
IS  - 0300-2977 (Linking)
VI  - 68
IP  - 1
DP  - 2010 Aug
TI  - Self-monitoring of blood glucose in tablet-treated type 2 diabetic patients 
      (ZODIAC).
PG  - 311-6
AB  - BACKGROUND: Whether self-monitoring of blood glucose (SMBG) improves glycaemic 
      control in patients with type 2 diabetes mellitus (T2DM) not using insulin is 
      questionable. Our aim was to investigate the effects of SMBG in patients with 
      T2DM who were in persistent moderate glycaemic control whilst not using insulin. 
      METHODS: Patients were eligible when between 18 and 70 years of age, with an 
      HbA1c between 7 and 8.5%, using one or two oral blood glucose lowering agents. 
      Forty-one of the anticipated 52 patients were randomly assigned to receive either 
      SMBG added to usual care, or to continue with usual care for one year. A fasting 
      glucose value and three postprandial glucose values were measured twice weekly 
      (including a Saturday or a Sunday). The primary efficacy parameter was HbA1c. 
      Furthermore, health-related quality of life and treatment satisfaction were 
      assessed using the Short-form 36 Health Survey Questionnaire (SF-36), the Type 2 
      Diabetes Symptom Checklist (DSC-r), the Diabetes Treatment Satisfaction 
      Questionnaire (DTSQ) and the WHO -Wellbeing Index (WHO-5). RESULTS: Change in 
      HbA1c between groups was -0.05% (95% CI: -0.51, 0.41; p=0.507). Also, there were 
      no significant changes between groups on the DTSQ , DSC type 2, WHO-5 or SF -36, 
      except for the SF -36 dimension 'health change' which was lower in the SBMG group 
      (mean difference: -12 (95% CI: -20.9, -3.1). CONCLUSION: On top of the absence of 
      a clinical benefit, tablet-treated T2DM patients experienced some worsening of 
      their health perception. We therefore argue that the use of SMBG in this patient 
      group is questionable, and its unlimited use and promotion should be 
      reconsidered.
FAU - Kleefstra, N
AU  - Kleefstra N
AD  - Diabetes Centre, Isala Clinics, Zwolle, the Netherlands. kleefstra@langerhans.com
FAU - Hortensius, J
AU  - Hortensius J
FAU - Logtenberg, S J J
AU  - Logtenberg SJ
FAU - Slingerland, R J
AU  - Slingerland RJ
FAU - Groenier, K H
AU  - Groenier KH
FAU - Houweling, S T
AU  - Houweling ST
FAU - Gans, R O B
AU  - Gans RO
FAU - van Ballegooie, E
AU  - van Ballegooie E
FAU - Bilo, H J G
AU  - Bilo HJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Neth J Med
JT  - The Netherlands journal of medicine
JID - 0356133
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Tablets)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Blood Glucose
MH  - Blood Glucose Self-Monitoring/methods
MH  - Confidence Intervals
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/psychology
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Health Status Indicators
MH  - Health Surveys
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Outpatients
MH  - Patient Satisfaction
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - Tablets
MH  - World Health Organization
MH  - Young Adult
EDAT- 2010/08/27 06:00
MHDA- 2011/03/08 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2011/03/08 06:00 [medline]
PST - ppublish
SO  - Neth J Med. 2010 Aug;68(1):311-6.